TVGN -
Tevogen Bio Holdings Inc. Common Stock
Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
0.7 0.04 (5.88%) |
--- |
--- |
0.0 (0.0%) |
0.0 (0.0%) |
0.05 (7.13%) |
-0.02 (-2.57%) |
-0.02 (-2.57%) |
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
Earnings & Ratios
- Basic EPS:
- -0.03
- Diluted EPS:
- -0.03
- Basic P/E:
- -24.6833
- Diluted P/E:
- -24.6833
- RSI(14) 1m:
- 100.0
- VWAP:
- 0.74
- RVol:
Events
Period |
Kind |
Movement |
Occurred At |
Related News
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
Oct 15, 2025 19:50
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
Sep 19, 2025 19:40
Tevogen CEO Donates Personal Shares to Support Local Law Enforcement
Aug 18, 2025 21:50
Healthcare AI Market Explodes 38.5% Annually as Diagnostics Gain FDA Traction
Aug 12, 2025 15:09
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
Aug 11, 2025 15:58
Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
Aug 06, 2025 19:59
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
Aug 05, 2025 18:32
Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
Aug 01, 2025 19:57
Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
Jul 18, 2025 16:36
From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine
Jul 16, 2025 22:35